NRX Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a net loss of $2.175 million for the third quarter and an accumulated deficit of $327.020 million.
Key Highlights
- Net loss of $2.175 million for the three months ended September 30, 2026, compared to a net loss of $5.890 million in the same period a year earlier, according to the filing.
- Net patient service revenue of $1.159 million for Q3 2026, up from $242 thousand in Q3 2025, as reported in the condensed consolidated statements of operations.
- Cash and cash equivalents of $19.822 million as of September 30, 2026, compared to $7.797 million as of December 31, 2025.
- Total stockholders' deficit improved to $1.986 million as of September 30, 2026, from a deficit of $15.937 million at December 31, 2025.
- Shares outstanding of 43,207,744 as of September 30, 2026, up from 31,734,333 at December 31, 2025, reflecting ATM offerings, an underwritten public offering, and stock-based issuances during the period.
- Nine-month net loss of $20.125 million for the period ended September 30, 2026, versus $28.982 million for the same nine-month period in 2025.
NRX Pharmaceuticals Financial Results for the Quarter Ended September 30, 2026
According to the filing, NRX Pharmaceuticals (NASDAQ:NRXP) reported a net loss of $2.175 million for the three months ended September 30, 2026, compared to a net loss of $5.890 million in the three months ended September 30, 2025. The company's basic and diluted net loss per share was $0.05 for Q3 2026, versus $0.27 in Q3 2025, based on weighted average shares of 43,171,238 and 22,231,178, respectively.
The filing disclosed total operating expenses of $9.304 million for the third quarter of 2026, driven primarily by selling, general and administrative expenses of $6.560 million and research and development costs of $1.808 million. Net patient service revenue grew to $1.159 million in Q3 2026 from $242 thousand in Q3 2025. The loss from operations was reported as $8.145 million for the quarter. Other income net of $5.970 million for Q3 2026 included a gain from the change in fair value of warrant liabilities of $6.204 million, which partially offset the operating loss.
On the balance sheet as of September 30, 2026, the registrant reported total assets of $27.815 million and total liabilities of $29.801 million. Warrant liabilities stood at $12.346 million, and accrued and other current liabilities were $11.768 million. During the nine months ended September 30, 2026, the company raised capital through an at-the-market offering and an underwritten public offering. The statement of changes in stockholders' deficit shows net proceeds from an underwritten public offering of $20.716 million in the second quarter of 2026, and ATM offering net proceeds of $3.424 million and $8.404 million in Q1 and Q2 2026, respectively. As of November 16, 2026, the registrant reported 44,327,982 shares of common stock outstanding.
What Was Disclosed
NRX Pharmaceuticals filed its quarterly report for the period ended September 30, 2026, disclosing a third-quarter net loss of $2.175 million, improved cash of $19.822 million, expanded patient service revenue, and a reduced stockholders' deficit compared to year-end 2025.





Please wait processing your request...